Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2011, Article ID 437348, 17 pages
http://dx.doi.org/10.1155/2011/437348
Review Article

Novel Immunotherapeutic Strategies of Gastric Cancer Treatment

1Department of Internal Medicine, University of Florence, Viale Morgagni 85, 50134 Florence, Italy
2Department of Biomedicine, Azienda Ospedaliera Universitaria Careggi, Viale Morgagni 85, 50134 Florence, Italy

Received 2 August 2011; Accepted 26 September 2011

Academic Editor: Walter J. Storkus

Copyright © 2011 Amedeo Amedei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. M. Parkin, “International variation,” Oncogene, vol. 23, no. 38, pp. 6329–6340, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. H. W. Bruckner, D. W. Kufe, R. E. Pollock, and R. R. Weichselbaum, Cancer Medicine, Ontario, Canda, 2003.
  3. D. Cunningham, W. H. Allum, S. P. Stenning et al., “MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer,” New England Journal of Medicine, vol. 355, pp. 11–20, 2006. View at Google Scholar
  4. J. Tepper, M. J. Krasna, D. Niedzwiecki et al., “Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781,” Journal of Clinical Oncology, vol. 26, no. 7, pp. 1086–1092, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. T. N. Walsh, N. Noonan, D. Hollywood, A. Kelly, N. Keeling, and T. P. Hennessy, “A comparison of multimodal therapy and surgery for esophageal adenocarcinoma,” New England Journal of Medicine, vol. 335, no. 7, pp. 462–467, 1996. View at Publisher · View at Google Scholar · View at Scopus
  6. J. S. Macdonald, S. R. Smalley, J. Benedetti et al., “Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction,” New England Journal of Medicine, vol. 345, no. 10, pp. 725–730, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. D. P. Kelsen, R. Ginsberg, T. F. Pajak et al., “Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer,” New England Journal of Medicine, vol. 339, no. 27, pp. 1979–1984, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. P. C. Enzinger and R. J. Mayer, “Esophageal cancer,” New England Journal of Medicine, vol. 349, no. 23, pp. 2241–2252, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. U. Vanhoefer, M. Tewes, F. Rojo et al., “Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor,” Journal of Clinical Oncology, vol. 22, no. 1, pp. 175–184, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. M. A. Shah, R. K. Ramanathan, D. H. Ilson et al., “Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma,” Journal of Clinical Oncology, vol. 24, no. 33, pp. 5201–5206, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. A. J. Ocean, F. Schnoll-Sussman, and R. Keresztes, “Phase II study of PS-341 (bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas (AGA),” Journal of Clinical Oncology, vol. 18, p. 14040, 2006. View at Google Scholar
  12. E. Elkord, R. E. Hawkins, and P. L. Stern, “Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy,” Expert Opinion on Biological Therapy, vol. 8, no. 4, pp. 385–395, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Amedei, E. Niccolai, C. Della Bella et al., “Characterization of tumor antigen peptide-specific T cells isolated from the neoplastic tissue of patients with gastric adenocarcinoma,” Cancer Immunology, Immunotherapy, vol. 58, no. 11, pp. 1819–1830, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. J. J. Goedert, “The epidemiology of acquired immunodeficiency syndrome malignancies,” Seminars in Oncology, vol. 27, no. 4, pp. 390–401, 2000. View at Google Scholar · View at Scopus
  15. M. Zeier, W. Hartschuh, M. Wiesel, T. Lehnert, and E. Ritz, “Malignancy after renal transplantation,” American Journal of Kidney Diseases, vol. 39, no. 1, p. E5, 2002. View at Google Scholar · View at Scopus
  16. G. B. Challis and H. J. Stam, “The spontaneous regression of cancer. A review of cases from 1900 to 1987,” Acta Oncologica, vol. 29, no. 5, pp. 545–550, 1990. View at Google Scholar · View at Scopus
  17. L. Zhang, J. R. Conejo-Garcia, D. Katsaros et al., “Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer,” New England Journal of Medicine, vol. 348, no. 3, pp. 203–213, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Nagorsen, C. Scheibenbogen, F. M. Marincola, A. Letsch, and U. Keilholz, “Natural T cell immunity against cancer,” Clinical Cancer Research, vol. 9, no. 12, pp. 4296–4303, 2003. View at Google Scholar · View at Scopus
  19. N. Ferrara, H. P. Gerber, and J. LeCouter, “The biology of VEGF and its receptors,” Nature Medicine, vol. 9, no. 6, pp. 669–676, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. W. Zou, “Regulatory T cells, tumour immunity and immunotherapy,” Nature Reviews Immunology, vol. 6, no. 4, pp. 295–307, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. C. M. Celluzzi, J. I. Mayordomo, W. J. Storkus, M. T. Lotze, and L. D. Falo Jr., “Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity,” Journal of Experimental Medicine, vol. 183, no. 1, pp. 283–287, 1996. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Caux, S. Ait-Yahia, K. Chemin et al., “Dendritic cell biology and regulation of dendritic cell trafficking by chemokines,” Springer Seminars in Immunopathology, vol. 22, no. 4, pp. 345–369, 2000. View at Google Scholar · View at Scopus
  23. C. G. Figdor, I. Jolanda, M. de Vries, W. Joost Lesterhuis, and C. J. M. Melief, “Dendritic cell immunotherapy: mapping the way,” Nature Medicine, vol. 10, no. 5, pp. 475–480, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Gilboa, “DC-based cancer vaccines,” Journal of Clinical Investigation, vol. 117, no. 5, pp. 1195–1203, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Ishigami, S. Natsugoe, K. Tokuda et al., “Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer,” Cancer Letters, vol. 159, no. 1, pp. 103–108, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Ishigami, S. Natsugoe, Y. Uenosono et al., “Infiltration of antitumor immunocytes into the sentinel node in gastric cancer,” Journal of Gastrointestinal Surgery, vol. 7, no. 6, pp. 735–739, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Galetto, M. Contarini, A. Sapino et al., “Ex vivo host response to gastrointestinal cancer cells presented by autologous dendritic cells,” Journal of Surgical Research, vol. 100, no. 1, pp. 32–38, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Kono, A. Takahashi, H. Sugai et al., “Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer,” Clinical Cancer Research, vol. 8, no. 11, pp. 3394–3400, 2002. View at Google Scholar · View at Scopus
  29. T. W. Kim, C. F. Hung, M. Ling et al., “Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins,” Journal of Clinical Investigation, vol. 112, no. 1, pp. 109–117, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. W. X. Zong, T. Lindsten, A. J. Ross, G. R. MacGregor, and C. B. Thompson, “BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak,” Genes and Development, vol. 15, no. 12, pp. 1481–1486, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. T. H. Kang, J. H. Lee, K. H. Noh et al., “Enhancing dendritic cell vaccine potency by combining a BAK/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments,” International Journal of Cancer, vol. 120, no. 8, pp. 1696–1703, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. T. W. Kim, C. F. Hung, D. Boyd et al., “Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies,” Journal of Immunology, vol. 171, no. 6, pp. 2970–2976, 2003. View at Google Scholar · View at Scopus
  33. T. H. Kang, J. H. Lee, K. H. Noh et al., “Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency,” Cancer Research, vol. 65, no. 1, pp. 309–316, 2005. View at Google Scholar · View at Scopus
  34. D. Park, N. Lapteva, M. Seethammagari, K. M. Slawin, and D. M. Spencer, “An essential role for Akt1 in dendritic cell function and tumor immunotherapy,” Nature Biotechnology, vol. 24, no. 12, pp. 1581–1590, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. Q. Yu, C. Kovacs, F. Y. Yue, and M. A. Ostrowski, “The role of the p38 mitogen-activated protein kinase, extracellular signal-regulated kinase, and phosphoinositide-3-OH kinase signal transduction pathways in CD40 ligand-induced dendritic cell activation and expansion of virus-specific CD8+ T cell memory responses,” Journal of Immunology, vol. 172, no. 10, pp. 6047–6056, 2004. View at Google Scholar · View at Scopus
  36. J. H. Kim, T. H. Kang, K. H. Noh et al., “Enhancement of DC vaccine potency by activating the PI3K/AKT pathway with a small interfering RNA targeting PTEN,” Immunology Letters, vol. 134, no. 1, pp. 47–54, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. N. R. Leslie, I. H. Batty, H. Maccario, L. Davidson, and C. P. Downes, “Understanding PTEN regulation: PIP2, polarity and protein stability,” Oncogene, vol. 27, no. 41, pp. 5464–5476, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. J. H. Kim, T. H. Kang, K. H. Noh et al., “Blocking the immunosuppressive axis with small interfering RNA targeting interleukin (IL)-10 receptor enhances dendritic cell-based vaccine potency,” Clinical and Experimental Immunology, vol. 165, no. 2, pp. 180–189, 2011. View at Publisher · View at Google Scholar
  39. S. B. He, K. Sun, L. Wang, D. C. Li, and Y. Y. Zhang, “GM-CSF gene-modified dendritic cell vaccine enhances antitumor immunity in vitro,” Zhonghua Zhong Liu Za Zhi, vol. 32, no. 6, pp. 410–414, 2010. View at Google Scholar
  40. S. Kim, K. Iizuka, H. L. Aguila, I. L. Weissman, and W. M. Yokoyama, “In vivo natural killer cell activities revealed by natural killer cell-deficient mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 6, pp. 2731–2736, 2000. View at Google Scholar · View at Scopus
  41. S. Coca, J. Perez-Piqueras, D. Martinez et al., “The prognostic significance of intratumoral natural killer cells in patients with colerectal carcinoma,” Cancer, vol. 79, no. 12, pp. 2320–2328, 1997. View at Publisher · View at Google Scholar · View at Scopus
  42. J. S. Orange and Z. K. Ballas, “Natural killer cells in human health and disease,” Clinical Immunology, vol. 118, no. 1, pp. 1–10, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. E. A. Grimm, A. Mazumder, H. Z. Zhang, and S. A. Rosenberg, “Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes,” Journal of Experimental Medicine, vol. 155, no. 6, pp. 1823–1841, 1982. View at Google Scholar · View at Scopus
  44. T. M. Law, R. J. Motzer, M. Mazumdar et al., “Phase III randomized trial of interleukin-2 with or without lymphokine- activated killer cells in the treatment of patients with advanced renal cell carcinoma,” Cancer, vol. 76, no. 5, pp. 824–832, 1995. View at Publisher · View at Google Scholar · View at Scopus
  45. U. S. Kammula, D. E. White, and S. A. Rosenberg, “Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer,” Cancer, vol. 83, no. 4, pp. 797–805, 1998. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Brune, S. Castaigne, J. Catalano et al., “Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial,” Blood, vol. 108, no. 1, pp. 88–96, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. M. B. Atkins, M. T. Lotze, J. P. Dutcher et al., “High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993,” Journal of Clinical Oncology, vol. 17, no. 7, pp. 2105–2116, 1999. View at Google Scholar
  48. R. M. Bukowski, “Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2,” Cancer, vol. 80, no. 7, pp. 1198–1220, 1997. View at Publisher · View at Google Scholar
  49. J. A. Gollob, J. W. Mier, K. Veenstra et al., “Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-γ induction is associated with clinical response,” Clinical Cancer Research, vol. 6, no. 5, pp. 1678–1692, 2000. View at Google Scholar · View at Scopus
  50. J. A. Gollob, K. G. Veenstra, R. A. Parker et al., “Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma,” Journal of Clinical Oncology, vol. 21, no. 13, pp. 2564–2573, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. M. J. Robertson, J. W. Mier, T. Logan et al., “Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer,” Clinical Cancer Research, vol. 12, no. 14, pp. 4265–4273, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. I. D. Davis, B. K. Skrumsager, J. Cebon et al., “An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma,” Clinical Cancer Research, vol. 13, no. 12, pp. 3630–3636, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. F. A. de Castro, P. V. Bonini Palma, F. R. Morais et al., “Immunological effects of interferon-α on chronic myelogenous leukemia,” Leukemia and Lymphoma, vol. 44, no. 12, pp. 2061–2067, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. W. Chen, A. S.H. Chan, A. J. Dawson, X. Liang, B. R. Blazar, and J. S. Miller, “FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function,” Biology of Blood and Marrow Transplantation, vol. 11, no. 1, pp. 23–34, 2005. View at Publisher · View at Google Scholar
  55. W. L. Gluck, D. Hurst, A. Yuen et al., “Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response,” Clinical Cancer Research, vol. 10, no. 7, pp. 2253–2264, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. K. D. Khan, C. Emmanouilides, D. M. Benson et al., “A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma,” Clinical Cancer Research, vol. 12, no. 23, pp. 7046–7053, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. J. G. Berdeja, A. Hess, D. M. Lucas et al., “Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab,” Clinical Cancer Research, vol. 13, no. 8, pp. 2392–2399, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. R. Parihar, P. Nadella, A. Lewis et al., “A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon γ production in a subset of patients,” Clinical Cancer Research, vol. 10, no. 15, pp. 5027–5037, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. C. Renner, F. Hartmann, W. Jung, C. Deisting, M. Juwana, and M. Pfreundschuh, “Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody,” Cancer Immunology Immunotherapy, vol. 49, no. 3, pp. 173–180, 2000. View at Google Scholar
  60. F. Hartmann, C. Renner, W. Jung et al., “Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines,” Clinical Cancer Research, vol. 7, no. 7, pp. 1873–1881, 2001. View at Google Scholar · View at Scopus
  61. C. J. Voskens, R. Watanabe, S. Rollins, D. Campana, K. Hasumi, and D. L. Mann, “Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity,” Journal of Experimental and Clinical Cancer Research, vol. 29, no. 1, article 134, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. Y. Kitagawa, M. Ueda, N. Ando, S. Ozawa, N. Shimizu, and M. Kitajima, “Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma,” Clinical Cancer Research, vol. 2, no. 5, pp. 909–914, 1996. View at Google Scholar · View at Scopus
  63. L. Gibault, J. P. Metges, V. Conan-Charlet et al., “Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer,” British Journal of Cancer, vol. 93, no. 1, pp. 107–115, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. N. W. Wilkinson, J. D. Black, E. Roukhadze et al., “Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma,” Journal of Gastrointestinal Surgery, vol. 8, no. 4, pp. 448–453, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. C. J. Allegra, J. M. Jessup, M. R. Somerfield et al., “American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy,” Journal of Clinical Oncology, vol. 27, no. 12, pp. 2091–2096, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. R. G. Amado, M. Wolf, M. Peeters et al., “Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1626–1634, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. E. van Cutsem, C. H. Köhne, E. Hitre et al., “Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer,” New England Journal of Medicine, vol. 360, no. 14, pp. 1408–1417, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. J. Baselga, L. Norton, H. Masui et al., “Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies,” Journal of the National Cancer Institute, vol. 85, no. 16, pp. 1327–1333, 1993. View at Google Scholar · View at Scopus
  69. Y. Kawaguchi, K. Kono, K. Mimura, H. Sugai, H. Akaike, and H. Fujii, “Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma,” International Journal of Cancer, vol. 120, no. 4, pp. 781–787, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. K. Imai and A. Takaoka, “Comparing antibody and small-molecule therapies for cancer,” Nature Reviews Cancer, vol. 6, no. 9, pp. 714–727, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. D. Cunningham, Y. Humblet, S. Siena et al., “Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer,” New England Journal of Medicine, vol. 351, no. 4, pp. 337–345, 2004. View at Publisher · View at Google Scholar · View at Scopus
  72. J. A. Bonner, P. M. Harari, J. Giralt et al., “Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck,” New England Journal of Medicine, vol. 354, no. 6, pp. 567–578, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. P. Enzinger, T. Yock, and W. Suh, “Phase II cisplatin, irinotecan, cetuximab and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer,” Journal of Clinical Oncology, vol. 24, p. 4064, 2006. View at Google Scholar
  74. H. Safran, M. Suntharalingam, T. Dipetrillo et al., “Cetuximab With concurrent chemoradiation for esophagogastric cancer: assessment of toxicity,” International Journal of Radiation Oncology Biology Physics, vol. 70, no. 2, pp. 391–395, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. T. Ruhstaller, M. Pless, D. Dietrich et al., “Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase lb-II trial (SAKK 75/06),” Journal of Clinical Oncology, vol. 29, pp. 626–631, 2011. View at Google Scholar
  76. F. de Vita, M. Orditura, E. Martinelli et al., “A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer,” British Journal of Cancer, vol. 104, no. 3, pp. 427–432, 2011. View at Publisher · View at Google Scholar
  77. A. Agarwala, N. Hanna, and A. McCollum, “Preoperative cetuximab and radiation (XRT) for patients (pts) with surgically resectable esophageal and gastroesophageal junction (GEJ) carcinomas: a pilot study from the Hoosier Oncology Group and the University of Texas Southwestern,” Journal of Clinical Oncology, vol. 27, p. 4557, 2009. View at Google Scholar
  78. H. Ma, T. Ryan, and E. Newman, “Neoadjuvant therapy of gastric cancer with irinotecan, cisplatin, and cetuximab followed by surgical resection and adjuvant chemoradiation,” in Proceedings of Graphics Interface American Society of Clinical Oncology (ASCO '09), vol. 58, 2009.
  79. D. H. Ilson, M. Bains, D. P. Kelsen et al., “Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer,” Journal of Clinical Oncology, vol. 21, no. 15, pp. 2926–2932, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. G. Ku, M. Bains, N. Rizk et al., “Phase II trial of pre-operative cisplatin/irinotecan and radiotherapy for locally advanced esophageal cancer: PET scan after induction therapy may identify early treatment failure,” in Proceedings of Graphics Interface American Society of Clinical Oncology (ASCO '07), vol. 9, 2007.
  81. M. Moehler, A. Mueller, T. Trarbach et al., “Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study,” Annals of Oncology, vol. 22, no. 6, pp. 1358–1366, 2011. View at Publisher · View at Google Scholar
  82. J. Galon, A. Costes, F. Sanchez-Cabo et al., “Type, density, and location of immune cells within human colorectal tumors predict clinical outcome,” Science, vol. 313, no. 5795, pp. 1960–1964, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. M. E. Dudley, J. R. Wunderlich, P. F. Robbins et al., “Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes,” Science, vol. 298, no. 5594, pp. 850–854, 2002. View at Publisher · View at Google Scholar · View at Scopus
  84. E. Y. Woo, C. S. Chu, T. J. Goletz et al., “Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer,” Cancer Research, vol. 61, no. 12, pp. 4766–4772, 2001. View at Google Scholar · View at Scopus
  85. C. H. June, “Principles of adoptive T cell cancer therapy,” Journal of Clinical Investigation, vol. 117, no. 5, pp. 1204–1212, 2007. View at Publisher · View at Google Scholar · View at Scopus
  86. J. Gutenberg-Universitat Mainz, D. Eberts, M. Fatho, V. Lennerz et al., “Melanoma-associated Mhc Class I associated oligopeptides and the uses thereof,” WO/2007/025760, 2007.
  87. A. Pharmaceuticals, “Cytotoxic T Lymphocyte-stimulation peptides for prevention, treatment, and diagnosis of melanoma,” WO/2001/032193, 2001.
  88. C. Yee, J. A. Thompson, D. Byrd et al., “Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 25, pp. 16168–16173, 2002. View at Publisher · View at Google Scholar · View at Scopus
  89. Y. J. Kim, J. Lim, J. S. Kang et al., “Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells,” Cancer Letters, vol. 33, no. 11, pp. 1789–1795, 2010. View at Publisher · View at Google Scholar
  90. D. Sangiolo, “Cytokine induced killer cells as promising immunotherapy for solid tumors,” Journal of Cancer, vol. 2, pp. 363–368, 2011. View at Google Scholar
  91. T. Hoshino, N. Seki, M. Kikuchi et al., “Hla class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer,” International Journal of Cancer, vol. 70, no. 6, pp. 631–638, 1997. View at Publisher · View at Google Scholar · View at Scopus
  92. K. Kono, Y. Rongcun, J. Charo et al., “Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes,” International Journal of Cancer, vol. 78, no. 2, pp. 202–208, 1998. View at Publisher · View at Google Scholar · View at Scopus
  93. D. L. Guo, M. Dong, L. Wang, L. P. Sun, and Y. Yuan, “Expression of gastric cancer-associated MG7 antigen in gastric cancer, precancerous lesions and H. pylori-associated gastric diseases,” World Journal of Gastroenterology, vol. 8, no. 6, pp. 1009–1013, 2002. View at Google Scholar · View at Scopus
  94. K. Wu, Y. Nie, C. Guo, Y. Chen, J. Ding, and D. Fan, “Molecular basis of therapeutic approaches to gastric cancer,” Journal of Gastroenterology and Hepatology, vol. 24, no. 1, pp. 37–41, 2009. View at Publisher · View at Google Scholar · View at Scopus
  95. Y. Nie, K. Wu, J. Yang et al., “Induction of T lymphocytes specific to human gastric cancer using HLA-A matched allogeneic gastric tumor cells,” Journal of Immunotherapy, vol. 26, no. 5, pp. 403–411, 2003. View at Publisher · View at Google Scholar · View at Scopus
  96. J. Jiang, N. Xu, C. Wu et al., “Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells,” Anticancer Research, vol. 26, no. 3 B, pp. 2237–2242, 2006. View at Google Scholar · View at Scopus
  97. C. Wu, J. Jiang, L. Shi, and N. Xu, “Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer,” Anticancer Research, vol. 28, no. 6 B, pp. 3997–4002, 2008. View at Google Scholar · View at Scopus
  98. S. Sun, X. M. Li, X. D. Li, and W. S. Yang, “Studies on inducing apoptosis effects and mechanism of CIK cells for MGC-803 gastric cancer cell lines,” Cancer Biotherapy and Radiopharmaceuticals, vol. 20, no. 2, pp. 173–180, 2005. View at Publisher · View at Google Scholar · View at Scopus
  99. R. B. Alexander and S. A. Rosenberg, “Long term survival of adoptively transferred tumor-infiltrating lymphocytes in mice,” Journal of Immunology, vol. 145, no. 5, pp. 1615–1620, 1990. View at Google Scholar · View at Scopus
  100. K. Kono, A. Takahashi, F. Ichihara et al., “Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial,” Clinical Cancer Research, vol. 8, no. 6, pp. 1767–1771, 2002. View at Google Scholar · View at Scopus
  101. S. A. Rosenberg, J. R. Yannelli, J. C. Yang et al., “Treatment of patients with metastatic melanoma with autologous tumor- infiltrating lymphocytes and interleukin 2,” Journal of the National Cancer Institute, vol. 86, no. 15, pp. 1159–1166, 1994. View at Google Scholar · View at Scopus
  102. M. E. Dudley, J. R. Wunderlich, T. E. Shelton, J. Even, and S. A. Rosenberg, “Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients,” Journal of Immunotherapy, vol. 26, no. 4, pp. 332–342, 2003. View at Publisher · View at Google Scholar · View at Scopus
  103. M. Tomšová, B. Melichar, I. Sedláková, and I. Šteiner, “Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma,” Gynecologic Oncology, vol. 108, no. 2, pp. 415–420, 2008. View at Publisher · View at Google Scholar
  104. J. Galon, A. Costes, F. Sanchez-Cabo et al., “Type, density, and location of immune cells within human colorectal tumors predict clinical outcome,” Science, vol. 313, no. 5795, pp. 1960–1964, 2006. View at Publisher · View at Google Scholar · View at Scopus
  105. W. Y. Ho, J. N. Blattman, M. L. Dossett, C. Yee, and P. D. Greenberg, “Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction,” Cancer Cell, vol. 3, no. 5, pp. 431–437, 2003. View at Publisher · View at Google Scholar · View at Scopus
  106. S. P. A. Molmed, C. Traversari, and C. Bordignon, “Antigen transduced T cells used as a delivery system for antigens,” WO/2004/035768, 2004.
  107. C. Bonini, G. Ferrari, S. Verzeletti et al., “HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia,” Science, vol. 276, no. 5319, pp. 1719–1724, 1997. View at Publisher · View at Google Scholar · View at Scopus
  108. T. Clackson, W. Yang, L. W. Rozamus et al., “Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 18, pp. 10437–10442, 1998. View at Publisher · View at Google Scholar · View at Scopus
  109. K. C. Straathof, D. M. Spencer, R. E. Sutton, and C. M. Rooney, “Suicide genes as safety switches in T lymphocytes,” Cytotherapy, vol. 5, no. 3, pp. 227–230, 2003. View at Publisher · View at Google Scholar · View at Scopus
  110. Yeda Research and Development Co, LTD, Z. Eshhar, D. Schindler, T. Waks, and G. Gross, “Chimeric receptor genes and cells transformed therewith,” WO/1993/019163, 1993.
  111. Fred Hutchinson Cancer Research Center, P. D. Greenberg, and B. H. Nelson, “Chimeric cytokine receptors in lymphocytes,” WO/1994/022914, 1994.
  112. M. S. Topp, S. R. Riddell, Y. Akatsuka, M. C. Jensen, J. N. Blattman, and P. D. Greenberg, “Restoration of CD28 expression in CD28- CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production,” Journal of Experimental Medicine, vol. 198, no. 6, pp. 947–955, 2003. View at Publisher · View at Google Scholar · View at Scopus
  113. Sierra Sciences Inc., W. H. Andrews, C. A. Foster, S. Fraser, and H. Mohammadpour, “Methods and compositions for modulating telomerase reverse transcriptase (Tert) expression,” WO/2002/016658, 2002.
  114. Y. Yarden and A. Ullrich, “Growth factor receptor tyrosine kinases,” Annual Review of Biochemistry, vol. 57, pp. 443–478, 1988. View at Google Scholar · View at Scopus
  115. T. J. Lynch Jr., E. S. Kim, B. Eaby, J. Garey, D. P. West, and M. E. Lacouture, “Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management,” Oncologist, vol. 12, no. 5, pp. 610–621, 2007. View at Publisher · View at Google Scholar · View at Scopus
  116. D. Schrag, K. Y. Chung, C. Flombaum, and L. Saltz, “Cetuximab therapy and symptomatic hypomagnesemia,” Journal of the National Cancer Institute, vol. 97, no. 16, pp. 1221–1224, 2005. View at Publisher · View at Google Scholar · View at Scopus
  117. Y. Itakura, H. Sasano, C. Shiga et al., “Epidermal growth factor receptor overexpression in esophageal carcinoma: an immunohistochemical study correlated with clinicopathologic findings and DNA amplification,” Cancer, vol. 74, no. 3, pp. 795–804, 1994. View at Publisher · View at Google Scholar · View at Scopus
  118. M. L. Janmaat, M. I. Gallegos-Ruiz, J. A. Rodriguez et al., “Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients,” Journal of Clinical Oncology, vol. 24, no. 10, pp. 1612–1619, 2006. View at Publisher · View at Google Scholar · View at Scopus
  119. N. I. Goldstein, M. Prewett, K. Zuklys, P. Rockwell, and J. Mendelsohn, “Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model,” Clinical Cancer Research, vol. 1, no. 11, pp. 1311–1318, 1995. View at Google Scholar · View at Scopus
  120. J. B. Vermorken, J. Trigo, R. Hitt et al., “Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy,” Journal of Clinical Oncology, vol. 25, no. 16, pp. 2171–2177, 2007. View at Publisher · View at Google Scholar · View at Scopus
  121. C. Pinto, F. di Fabio, S. Siena et al., “Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study),” Annals of Oncology, vol. 18, no. 3, pp. 510–517, 2007. View at Publisher · View at Google Scholar · View at Scopus
  122. F. Lordick, B. Luber, S. Lorenzen et al., “Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO),” British Journal of Cancer, vol. 102, no. 3, pp. 500–505, 2010. View at Publisher · View at Google Scholar · View at Scopus
  123. S. Lorenzen, T. Schuster, R. Porschen et al., “Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie,” Annals of Oncology, vol. 20, no. 10, pp. 1667–1673, 2009. View at Publisher · View at Google Scholar · View at Scopus
  124. K. Yeh, C. Hsu, and C. Hsu, “Phase II study of cetuximab plus weekly cisplatin and 24-hour infusion of high-dose 5-fluorouracil and leucovorin for the first-line treatment of advanced gastric cancer,” Journal of Clinical Oncology, vol. 27, p. 4567, 2009. View at Google Scholar
  125. X. Zhang, J. Xu, and L. Shen, “A phase II study of cetuximab with cisplatin and capecitabine as first-line treatment in advanced gastric cancer,” in Proceedings of Graphics Interface American Society of Clinical Oncology (ASCO '09), vol. 39, 2009.
  126. C. Pinto, F. di Fabio, C. Barone et al., “Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study),” British Journal of Cancer, vol. 101, no. 8, pp. 1261–1268, 2009. View at Publisher · View at Google Scholar · View at Scopus
  127. E. Woell, T. Kühr, W. Eisterer et al., “Biweekly oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. A first-line multicenter phase II trial of the arbeitsgemeinschaft medikamentoese tumortherapie (AGMT),” Anticancer Research, vol. 28, pp. 2901–2905, 2008. View at Google Scholar
  128. P. Gold, B. Goldman, S. Iqbal et al., “Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II southwest oncology group study (S0415),” Journal of Thoracic Oncology, vol. 5, no. 9, pp. 1472–1476, 2010. View at Publisher · View at Google Scholar · View at Scopus
  129. G. Ku, M. Shah, and L. Tang, “Cetuximab (C225) plus irinotecan/cisplatin (CPT/ CDDP) for CPT/CDDP-refractory esophageal cancer,” in Proceedings of the Graphics Interface American Society of Clinical Oncology (ASCO '08), vol. 54, 2008.
  130. N. Tebbutt, M. M. Cummins, T. Sourjina et al., “Australasian Gastro-Intestinal Trials Group. Randomized, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracilor with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial,” British Journal of Cancer, vol. 102, pp. 475–481, 2010. View at Google Scholar
  131. K. Schønnemann, J. Bjerregaard, and H. Jensen, “Biweekly cetuximab and irinotecan as second-line therapy to patients with platinium-resistant gastroesophageal cancer,” in Proceedings of the Graphics Interface American Society of Clinical Oncology (GI ASCO '09), vol. 73, 2009.
  132. U. Vanhoefer, M. Tewes, F. Rojo et al., “Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor,” Journal of Clinical Oncology, vol. 22, no. 1, pp. 175–184, 2004. View at Publisher · View at Google Scholar · View at Scopus
  133. S. Rao, N. Starling, D. Cunningham et al., “Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer,” British Journal of Cancer, vol. 99, no. 6, pp. 868–874, 2008. View at Publisher · View at Google Scholar · View at Scopus
  134. E. van Cutsem, M. Peeters, S. Siena et al., “Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 25, no. 13, pp. 1658–1664, 2007. View at Publisher · View at Google Scholar · View at Scopus
  135. K. Foon, X. D. Yang, L. M. Weiner et al., “Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody,” International Journal of Radiation Oncology Biology Physics, vol. 58, no. 3, pp. 984–990, 2004. View at Publisher · View at Google Scholar · View at Scopus
  136. P. Casalini, M. V. Iorio, E. Galmozzi, and S. Ménard, “Role of HER receptors family in development and differentiation,” Journal of Cellular Physiology, vol. 200, no. 3, pp. 343–350, 2004. View at Publisher · View at Google Scholar
  137. M. Al-Kasspooles, J. H. Moore, M. B. Orringer, and D. G. Beer, “Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas,” International Journal of Cancer, vol. 54, no. 2, pp. 213–219, 1993. View at Publisher · View at Google Scholar · View at Scopus
  138. J. S. Ross and B. J. McKenna, “The HER-2/neu oncogene in tumors of the gastrointestinal tract,” Cancer Investigation, vol. 19, no. 5, pp. 554–568, 2001. View at Publisher · View at Google Scholar · View at Scopus
  139. T. P. Brien, R. D. Odze, C. E. Sheehan, B. J. McKenna, and J. S. Ross, “Her-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma,” Human Pathology, vol. 31, no. 1, pp. 35–39, 2000. View at Google Scholar · View at Scopus
  140. C. A. Hudis, “Trastuzumab—mechanism of action and use in clinical practice,” New England Journal of Medicine, vol. 357, no. 1, pp. 39–51, 2007. View at Publisher · View at Google Scholar · View at Scopus
  141. M. J. Piccart-Gebhart, M. Procter, B. Leyland-Jones et al., “Herceptin Adjuvant (HERA) Trial Study Team Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer,” New England Journal of Medicine, vol. 353, pp. 1659–1672, 2005. View at Google Scholar
  142. E. H. Romond, E. A. Perez, J. Bryant et al., “Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer,” New England Journal of Medicine, vol. 353, no. 16, pp. 1673–1684, 2005. View at Publisher · View at Google Scholar · View at Scopus
  143. I. Smith, M. Procter, R. D. Gelber et al., “HERA study team. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial,” Lancet, vol. 369, pp. 29–36, 2007. View at Google Scholar
  144. M. A. Cobleigh, C. L. Vogel, D. Tripathy et al., “Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease,” Journal of Clinical Oncology, vol. 17, no. 9, pp. 2639–2648, 1999. View at Google Scholar · View at Scopus
  145. C. L. Vogel, M. A. Cobleigh, D. Tripathy et al., “Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer,” Journal of Clinical Oncology, vol. 20, no. 3, pp. 719–726, 2002. View at Publisher · View at Google Scholar · View at Scopus
  146. D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2,” New England Journal of Medicine, vol. 344, no. 11, pp. 783–792, 2001. View at Publisher · View at Google Scholar · View at Scopus
  147. S. A. Crone, Y. Y. Zhao, L. Fan et al., “ErbB2 is essential in the prevention of dilated cardiomyopathy,” Nature Medicine, vol. 8, no. 5, pp. 459–465, 2002. View at Publisher · View at Google Scholar · View at Scopus
  148. A. Seidman, C. Hudis, M. K. Pierri et al., “Cardiac dysfunction in the trastuzumab clinical trials experience,” Journal of Clinical Oncology, vol. 20, no. 5, pp. 1215–1221, 2002. View at Publisher · View at Google Scholar · View at Scopus
  149. H. Safran, T. DiPetrillo, P. Akerman et al., “Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma,” International Journal of Radiation Oncology Biology Physics, vol. 67, no. 2, pp. 405–409, 2007. View at Publisher · View at Google Scholar · View at Scopus
  150. J. Y. Bang, E. van Cutsem, A. Feyereislova et al., “ToGA Trial Investigators Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial,” Lancet, vol. 376, pp. 687–697, 2010. View at Google Scholar
  151. F. A. Eskens and J. Verweij, “The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review,” European Journal of Cancer, vol. 42, no. 18, pp. 3127–3139, 2006. View at Publisher · View at Google Scholar · View at Scopus
  152. N. Ferrara and T. Davis-Smyth, “The biology of vascular endothelial growth factor,” Endocrine Reviews, vol. 18, no. 1, pp. 4–25, 1997. View at Publisher · View at Google Scholar · View at Scopus
  153. K. Inoue, Y. Ozeki, T. Suganuma, Y. Sugiura, and S. Tanaka, “Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression,” Cancer, vol. 79, no. 2, pp. 206–213, 1997. View at Publisher · View at Google Scholar · View at Scopus
  154. Y. Kitadai, K. Haruma, T. Tokutomi et al., “Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas,” Clinical Cancer Research, vol. 4, no. 9, pp. 2195–2200, 1998. View at Google Scholar · View at Scopus
  155. A. Kleespies, M. Guba, K. W. Jauch, and C. J. Bruns, “Vascular endothelial growth factor in esophageal cancer,” Journal of Surgical Oncology, vol. 87, no. 2, pp. 95–104, 2004. View at Publisher · View at Google Scholar · View at Scopus
  156. C. H. Shih, S. Ozawa, N. Ando, M. Ueda, and M. Kitajima, “Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus,” Clinical Cancer Research, vol. 6, no. 3, pp. 1161–1168, 2000. View at Google Scholar · View at Scopus
  157. A. Imdahl, G. Bognar, J. Schulte-Mönting, U. Schöffel, E. H. Farthmann, and C. Ihling, “Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer,” European Journal of Cardio-thoracic Surgery, vol. 21, no. 4, pp. 657–663, 2002. View at Publisher · View at Google Scholar · View at Scopus
  158. H. Shimada, T. Hoshino, S. Okazumi et al., “Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma,” British Journal of Cancer, vol. 86, no. 4, pp. 552–557, 2002. View at Publisher · View at Google Scholar · View at Scopus
  159. K. Maeda, Y. S. Chung, Y. Ogawa et al., “Prognostic value of vascular endothelial growth factor expression in gastric carcinoma,” Cancer, vol. 77, no. 5, pp. 858–863, 1996. View at Publisher · View at Google Scholar · View at Scopus
  160. T. Yoshikawa, A. Tsuburaya, O. Kobayashi et al., “Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma,” Cancer Letters, vol. 153, no. 1-2, pp. 7–12, 2000. View at Publisher · View at Google Scholar · View at Scopus
  161. H. Hurwitz, L. Fehrenbacher, W. Novotny et al., “Kabbinavar bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer,” New England Journal of Medicine, vol. 350, no. 23, pp. 2335–2342, 2004. View at Publisher · View at Google Scholar · View at Scopus
  162. A. Sandler, R. Gray, M. C. Perry et al., “Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer,” New England Journal of Medicine, vol. 355, no. 24, pp. 2542–2550, 2006. View at Publisher · View at Google Scholar · View at Scopus
  163. K. Miller, M. Wang, J. Gralow et al., “Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer,” New England Journal of Medicine, vol. 357, no. 26, pp. 2666–2676, 2007. View at Publisher · View at Google Scholar · View at Scopus
  164. R. K. Jain, “Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy,” Nature Medicine, vol. 7, no. 9, pp. 987–989, 2001. View at Publisher · View at Google Scholar · View at Scopus
  165. C. G. Willett, Y. Boucher, E. di Tomaso et al., “Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer,” Nature Medicine, vol. 10, no. 2, pp. 145–147, 2004. View at Publisher · View at Google Scholar · View at Scopus
  166. M. A. Shah, D. Ilson, and D. P. Kelsen, “Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy,” Journal of Clinical Oncology, vol. 23, no. 11, pp. 2574–2576, 2005. View at Publisher · View at Google Scholar · View at Scopus
  167. M. A. Shah, M. Jhawer, D. H. Ilson et al., “Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma,” Journal of Clinical Oncology, vol. 29, no. 7, pp. 868–874, 2011. View at Publisher · View at Google Scholar
  168. P. Enzinger, D. Ryan, J. W. Clark et al., “Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer,” Annals of Oncology, vol. 20, no. 3, pp. 475–480, 2009. View at Publisher · View at Google Scholar · View at Scopus
  169. B. El-Rayes, M. Zalupski, T. Bekai-Saab et al., “A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers,” Annals of Oncology, vol. 21, no. 10, pp. 1999–2004, 2010. View at Publisher · View at Google Scholar · View at Scopus
  170. P. Enzinger, P. Fidias, and J. Meyerhardt, “Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer,” in Proceedings of the Graphics Interface American Society of Clinical Oncology (ASCO '06), vol. 68, 2006.
  171. A. I. Einzig, D. Neuberg, S. C. Remick et al., “Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293,” Medical Oncology, vol. 13, no. 2, pp. 87–93, 1996. View at Google Scholar · View at Scopus
  172. E. I. Heath, S. Urba, J. Marshall, S. Piantadosi, and A. A. Forastiere, “Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus,” Investigational New Drugs, vol. 20, no. 1, pp. 95–99, 2002. View at Publisher · View at Google Scholar · View at Scopus